San Diego, CA -- (SBWIRE) -- 02/15/2017 -- A deadline is coming up on March 7, 2017 in the lawsuit filed for certain investors of TG Therapeutics Inc (NASDAQ:TGTX over alleged securities laws violations by TG Therapeutics.

Investors who purchased shares of TG Therapeutics Inc (NASDAQ:TGTX) have certain options and there are strict and short deadlines running. Deadline: March 7, 2017. NASDAQ:TGTX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of TG Therapeutics Inc (NASDAQ:TGTX) common shares between September 15, 2014 and October 12, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between September 15, 2014 and October 12, 2016 TG Therapeutics Inc alegedly misrepresented and/or omitted material information concerning its GENUINE Phase III clinical trial for its proprietary combination of drug therapies TG-1101 and TGR-1202.

The Phase III trial consisted of two parts, Part I evaluating the effect of the addition of TG-1101 to ibrutinib on overall response rate (ORR) in approximately 200 patients, and Part II evaluating the effect of the addition of TG-1101 to ibrutinib on progression-free survival (PFS) in all study patients.

On October 13, 2016, TG Therapeutics Inc that it had filed with the FDA an amended protocol for its leukemia drug combination, GENUINE Phase 3 Trial. In the amendments, the Company eliminated part II of the GENUINE study and reduced the number of randomized patients from 200 to approximately 120. The Company no longer benefits from of its previously negotiated Special Protocol Assessment with the FDA.

Those who purchased shares of TG Therapeutics Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com